Trials / Completed
CompletedNCT00724048
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 227 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACR16 | ACR16 will be administered per dose and schedule specified in the arm description. |
| OTHER | Placebo | Placebo matching to ACR16 will be administered per schedule specified in the arm description. |
Timeline
- Start date
- 2008-10-24
- Primary completion
- 2010-07-26
- Completion
- 2010-07-26
- First posted
- 2008-07-29
- Last updated
- 2023-08-31
- Results posted
- 2023-08-31
Locations
28 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00724048. Inclusion in this directory is not an endorsement.